Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich's Ataxia by Marta Seco-Cervera, Pilar González-Cabo, Federico V. Pallardó, Carlos Romá-Mateo, José Luis García-Giménez

Connect to this object online.

Two different pathogenic mechanisms, dying-back axonal neuropathy and pancreatic senescence, are present in the YG8R mouse model of Friedreich's ataxia by Belén Mollá, Fátima Riveiro, Arantxa Bolinches-Amorós, Diana C. Muñoz-Lasso, Francesc Palau, Pilar González-Cabo

Connect to this object online.

Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion? by Laura R. Rodríguez, Tamara Lapeña, Pablo Calap-Quintana, María Dolores Moltó, Pilar Gonzalez-Cabo, Juan Antonio Navarro Langa

Connect to this object online.

Therapeutic Strategies Targeting Mitochondrial Calcium Signaling: A New Hope for Neurological Diseases? by Laura R. Rodríguez, Tamara Lapeña-Luzón, Noelia Benetó, Vicent Beltran-Beltran, Federico V. Pallardó, Pilar Gonzalez-Cabo, Juan Antonio Navarro

Connect to this object online.

Regulatory drugs of glutamate transporter 1 (EAAT2/GLT-1) expression and activity: role in quenching oxidative damage by Davinia Domínguez-González, Blanca Romero-Llopis, Marta Roldán-Lázaro, Lorena Baquero, Rita Noverques, Federico V Pallardó, Juan Antonio Navarro, Pilar Gonzalez-Cabo

Connect to this object online.